Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS.
Seth C HopkinsAjay OgiralaMaryAlice WordenKenneth S KoblanPublished in: Clinical drug investigation (2021)
NCT0296938, NCT00088634, NCT00549718, NCT00615433, NCT00790192.
Keyphrases